Prodrug Design for Brain Delivery of Small- and Medium-Sized Neuropeptides

Methods in Molecular Biology

Volumn 789, Issue , 2011, Pages 313-336

  Prokai Tatrai, Katalin ^a   Prokai, Laszlo ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Analeptic effect; Bioactivation; Blood brain barrier; Immobilized artificial membrane chromatography; Lipophilicity; Neuropeptide; Neuropharmacology; Prodrug; Solid phase peptide synthesis; Thyrotropin releasing hormone analogue

Indexed keywords

DRUG DERIVATIVE; NEUROPEPTIDE; PRODRUG; PROTIRELIN;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHEMICAL STRUCTURE; METABOLISM; MOUSE; RAT; SOLID PHASE SYNTHESIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; MICE; MOLECULAR STRUCTURE; NEUROPEPTIDES; PRODRUGS; RATS; SOLID-PHASE SYNTHESIS TECHNIQUES; THYROTROPIN-RELEASING HORMONE;

EID: 80054737357     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-310-3_21     Document Type: Chapter

References (40)

1. Strand, F.L. (2003) Neuropeptides: general characteristics and neuropharmaceutical potential in treating CNS disorders In: Prokai, L., and Prokai-Tatrai, K. (eds) Peptide transport and delivery into the central nervous system, Vol. 61, Birkhäuser, Basel.
2. Prokai, L. (2002) Targeting drugs into the central nervous system. In Muzykantow, V.R., and Torchilin, V. (eds) Biomedical aspects of drug targeting, Kluwer Academic Publishers, Dordrecht.
3. Kusuhara, H., and Sugiyama, Y. (2001) Efflux transport systems for drugs at the blood–brain barrier and blood–cerebrospinal fluid barrier (Part 1). Drug Discov. Today 6, 150–156.
4. Begley, D.J., and Brightman, M.W. (2003) Structural and functional aspects of the blood– brain barrier. In: Prokai, L., and Prokai-Tatrai, K. (eds) Peptide transport and delivery into the central nervous system, Vol. 61, Birkhäuser, Basel.
5. Brownlees, J., and Williams, C.H. (1993) Peptidases, peptides at the mammalian blood– brain barrier. J. Neurochem. 60, 793–803.
6. Pardridge, W.J. (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nature Rev. Drug Discovery 1, 131–139.
7. Albert, A, (1958) Chemical aspects of selective toxicity. Nature 182, 421–422.
8. Prokai-Tatrai, K., and Prokai, L. (2003) Modifying peptide properties by prodrug design for enhanced transport into the CNS. In: Prokai, L., and Prokai-Tatrai, K. (eds) Peptide transport and delivery into the central nervous system, Vol. 61, Birkhäuser, Basel.
9. Wong, A., and Toth, I. (2001) Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem. 8, 1123–1136.
10. Powell, M.F. (1993). Peptide stability in drug development: in vitro peptide degradation in plasma and serum. Ann. Rep. Med. Chem. 28, 285–294.
11. 2 and its prodrugs as central nervous system agents. Med. Chem. 1, 141–152.
12. 2 . Bioorg. Med. Chem. Lett. 13, 1011–10144.
13. Prokai-Tatrai, K., and Prokai, L. (1996) Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J. Med. Chem. 39, 4775–4782.
14. Prokai-Tatrai, K., Kim, H.S., and Prokai, L. (2008) The utility of oligopeptidase in brain-targeting deliver y of an enkephalin analogue by prodrug design. Open Med. Chem. J. 2, 97–100.
15. Prokai, L., Prokai-Tatrai, K., Zharikova, A.D. et al. (2004) Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J. Med. Chem. 47, 625–6033.
16. Klon, A.E. (2009) Computational models for central nervous system penetration. Curr. Med. Chem. 5, 71–89.
17. Danielsson, L.G., and Zhang, Y.H. (1996) Methods for determining n-octanol-water partition constants. TRAC–Trends Anal. Chem. 15, 188–196.
18. Ong, S., Hanlan, C., and Pidgeon, J. (1996) Immobilized-artificial-membrane chromatography: Measurements of membrane partition coefficient and predicting drug membrane permeability. J. Chromatogr. 728, 13–128.
19. Faller, B. (2008) Artificial membrane assays to assess permeability. Curr. Drug Metab. 9, 886–892.
20. Deli, M.A., Abraham, C.S., Kataoka, Y. et al. (2005) Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell Mol. Neurobiol. 25, 59–129.
21. Bradbury, M.W.B., Patlak, C.S., and Oldendorf, W.H. (1975) Analysis of brain uptake and loss of radiotracers after intracarotid injection. Am. J. Physiol. 229, 1110–1115.
22. Prokai, L., Zharikova, A.D., Janaky T et al. (2000) Exploratory pharmacokinetics and brain distribution study of a neuropeptide FF antagonist by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 14, 2412–2418.
23. Hansch, C., and Clayton, J.M. (1973) Lipophilic character and biological-activity of drugs. 2. Parabolic case. J. Pharm. Sci. 62, 1–21.
24. Summerfield, S.G., Read, K., Begley, D.J. et al.(2007) Central ner vous system drug disposition: The relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322, 205–213.
25. Del Rio-Garcia, J., and Smyth, D.G. (1990) Distribution of pyroglutamylpeptide amides related to thyrotropin-releasing hormone in the central nervous system and periphery of the rat. J. Endocrinol. 127, 445–450.
26. Prokai, L. (2002) Central nervous system effects of thyrotropin-releasing hormone and its analogues: opportunities and perspectives for drug discovery and development. In: Jucker, E.M. (ed) Progress in drug research, Vol 59, Birkhäuser, Basel.
27. Prokai-Tatrai, K., Prokai, L. (2009) Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents. Molecules 14, 633–654.
28. Kelly, J.A., Slator, G.R., Tipton, K.F. et al. (2000) Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides. J. Biol. Chem. 275, 16746–16751.
29. 2 and thyrotropin-releasing hormone in the brain. Neurosci. Lett. 415, 64–67.
30. 2]TRH dose-dependently attenuates TRH-evoked analeptic effect in the mouse brain. Brain Res. Bull. 82, 83–86.
31. Merrifield, R.B. (1963) Solid phase peptide synthesis. Synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149–2154.
32. Carpino, L.A., and Han, G.Y. (1972) 9-Fluorenylmethoxycarbonyl amino-protecting group. J. Org. Chem. 37, 3404–3409.
33. Albericio, F., Bofill, J.M., El-Faham, A. et al. (1998) Use of onium salt-based coupling reagents in peptide synthesis. J. Org. Chem. 63, 9678–9683.
34. Kaiser, E., Colescott, R.L., Bossinger, C.D. et al. (1970) Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 34, 595–598.
35. Mant, C.T.; and Hodges, R.S. (1991). High-performance liquid chromatography of peptides and proteins; CRC Press: Boca Raton, Fl.
36. Prokai, L., Zharikova, A., Janáky, T. et al. (2001) Integration of mass spectrometry into early-phase discovery and development of central nervous system agents. J. Mass Spectrom. 36, 1211–1219.
37. Braddy, A.C., Janaky, T., and Prokai, L. (2002) Immobilized artificial membrane chromatography coupled with atmospheric pressure ionization mass spectrometry. J. Chromatogr. A 966, 81–87.
38. ht t p: //www. r egi s t ech. com/I nf oPages / IamInfo/IamCareAndUse.html
39. Vojkovsky, T. (1995) Detection of secondary amine on solid phase. Pept. Res. 8, 236–237.
40. 50 ) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108.